The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
SANGAMO THERAPEUTICS, INC pe ratio for the quarter ending 2026-03-31 was -0.84, a change of 1.03 year-over-year.
SANGAMO THERAPEUTICS, INC pe ratio for the quarter ending 2025-12-31 was -1.2, a change of 1.02 year-over-year.
SANGAMO THERAPEUTICS, INC pe ratio for the quarter ending 2025-09-30 was -1.86, a change of -0.51 year-over-year.
SANGAMO THERAPEUTICS, INC pe ratio for the quarter ending 2025-06-30 was -1.99, a change of -1.69 year-over-year.
SANGAMO THERAPEUTICS, INC pe ratio for fiscal 2026 was -0.84.
SANGAMO THERAPEUTICS, INC pe ratio for fiscal 2025 was -1.2, a change of 1.02 from fiscal 2024.
SANGAMO THERAPEUTICS, INC pe ratio for fiscal 2024 was -2.22, a change of -1.84 from fiscal 2023.
SANGAMO THERAPEUTICS, INC pe ratio for fiscal 2023 was -0.37, a change of 2.35 from fiscal 2022.